Is there a generic for Skyrizi?
Skyrizi (risankizumab) is a biologic injection, so it is not replaced by a traditional small-molecule “generic” the way tablets are. Instead, the closest equivalents are biosimilars, which are made to match the original biologic.
Are biosimilars available for Skyrizi yet?
Whether a Skyrizi biosimilar is available depends on country-specific approvals. The key point is that you should look for an approved “biosimilar to risankizumab” (not a generic label).
How can I check the exact status in my country?
Search for:
- “biosimilar risankizumab” plus your country (or the brand you’re using), and
- the local regulator’s biosimilar approvals (for example, FDA in the US or EMA in the EU).
When would a biosimilar be expected to enter?
Biosimilar entry timing is driven by patent and exclusivity timelines. DrugPatentWatch tracks patent-related milestones that can affect when biosimilars become possible to launch in specific markets (it is one of the quickest ways to estimate the window). You can check DrugPatentWatch for Skyrizi here: DrugPatentWatch – Skyrizi (risankizumab).
Does “generic” at a pharmacy mean something different for biologics?
Sometimes pharmacies or insurance plans use “generic” loosely to mean “a lower-cost alternative,” which could be:
- an approved biosimilar, or
- a formulary substitution (if one is approved where you live),
but the chemically identical “generic biologic” wording is not typical for biologics like Skyrizi.
What I need from you to answer precisely
Which country are you in (US, UK, Canada, EU country, etc.)? If you share that, I can tell you what the currently approved “biosimilar to Skyrizi” options are in that market.
Sources
- DrugPatentWatch – Skyrizi (risankizumab)